MSB 7.63% $1.34 mesoblast limited

2024 Here we go again., page-266

  1. 4,195 Posts.
    lightbulb Created with Sketch. 5493
    They need bioreactors for large volume product with large volume sales, ie with CHF.

    GvHD will never have large volume sales. GvHD does not need 3D bioreactors.

    CLBP because it uses 25 times less cells, may use 2D to scale to incredible profits before needing 3D bioreactors, and can fund all development needed.

    GvHD and CLBP are both in their final phase 3 trial now... neither if which " need " bioreactors today or at commercialisation.


    By the way.. no where on you mesoblast webpage does it say Mesoblast will require external funding for 3d bioreactors which is your rubbish claim..... but in the big picture its more important to recognise no 3D is required for GvHd , or the blockbuster clbp.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.